Net Cash Provided by (Used in) Financing Activities in USD of AN2 Therapeutics, Inc. from Q1 2021 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
AN2 Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2021 to Q1 2025.
  • AN2 Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was $65M, a 18525% increase year-over-year.
  • AN2 Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $372K, a 99.6% decline from 2023.
  • AN2 Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $85M, a 20.8% increase from 2022.
  • AN2 Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $70.4M, a 10.4% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

AN2 Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $65M +$64.7M +18525% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-13
Q1 2024 $349K +$150K +75.4% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-13
Q1 2023 $199K -$63M -99.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q1 2022 $63.2M -$16.6M -20.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q1 2021 $79.7M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10

AN2 Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $372K -$84.6M -99.6% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-25
2023 $85M +$14.6M +20.8% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-25
2022 $70.4M -$8.18M -10.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-29
2021 $78.5M Jan 1, 2021 Dec 31, 2021 10-K 2023-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.